146 related articles for article (PubMed ID: 30282071)
1. Upregulation of P21-Activated Kinase 1 (PAK1)/CREB Axis in Squamous Non-Small Cell Lung Carcinoma.
Chung JH; Kim DH; Kim YS; Son BS; Kim D; Hwang C; Shin D; Noh SG; Han JH; Kim DK; Kim JH; Koo JS; Chung HY; Yoon SH
Cell Physiol Biochem; 2018; 50(1):304-316. PubMed ID: 30282071
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of PAK1 Inhibits the Proliferation and Invasion of Non-Small Cell Lung Cancer Cells Through the ERK Pathway.
Wang S; Wang SY; Du F; Han Q; Wang EH; Luo EJ; Liu Y
Appl Immunohistochem Mol Morphol; 2020 Sep; 28(8):602-610. PubMed ID: 31394555
[TBL] [Abstract][Full Text] [Related]
3. Blockage of PAK1 alleviates the proliferation and invasion of NSCLC cells via inhibiting ERK and AKT signaling activity.
Song P; Song B; Liu J; Wang X; Nan X; Wang J
Clin Transl Oncol; 2021 Apr; 23(4):892-901. PubMed ID: 32974862
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of P21-activated kinase 4 is associated with poor prognosis in non-small cell lung cancer and promotes migration and invasion.
Cai S; Ye Z; Wang X; Pan Y; Weng Y; Lao S; Wei H; Li L
J Exp Clin Cancer Res; 2015 May; 34(1):48. PubMed ID: 25975262
[TBL] [Abstract][Full Text] [Related]
5. Circular RNA hsa_circ_0004396 acts as a sponge of miR-615-5p to promote non-small cell lung cancer progression and radioresistance through the upregulation of P21-Activated Kinase 1.
Li D; Yan L; Zhang J; Gu F
J Clin Lab Anal; 2022 Jun; 36(6):e24463. PubMed ID: 35500159
[TBL] [Abstract][Full Text] [Related]
6. Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma.
Ito M; Codony-Servat C; Codony-Servat J; Lligé D; Chaib I; Sun X; Miao J; Sun R; Cai X; Verlicchi A; Okada M; Molina-Vila MA; Karachaliou N; Cao P; Rosell R
Cell Commun Signal; 2019 Oct; 17(1):137. PubMed ID: 31660987
[TBL] [Abstract][Full Text] [Related]
7. PAK1 overexpression promotes cell proliferation in cutaneous T cell lymphoma via suppression of PUMA and p21.
Wang Y; Gu X; Li W; Zhang Q; Zhang C
J Dermatol Sci; 2018 Apr; 90(1):60-67. PubMed ID: 29307600
[TBL] [Abstract][Full Text] [Related]
8. Cyclic GMP/protein kinase G type-Iα (PKG-Iα) signaling pathway promotes CREB phosphorylation and maintains higher c-IAP1, livin, survivin, and Mcl-1 expression and the inhibition of PKG-Iα kinase activity synergizes with cisplatin in non-small cell lung cancer cells.
Wong JC; Bathina M; Fiscus RR
J Cell Biochem; 2012 Nov; 113(11):3587-98. PubMed ID: 22740515
[TBL] [Abstract][Full Text] [Related]
9. Mogrol-mediated enhancement of radiotherapy sensitivity in non-small cell lung cancer: a mechanistic study.
Yin Z; Zhang X; Sun X; Huo Y; Ji N; Chen K
Am J Physiol Cell Physiol; 2024 Jun; 326(6):C1753-C1768. PubMed ID: 38682239
[TBL] [Abstract][Full Text] [Related]
10. Growth suppression of lung cancer cells by targeting cyclic AMP response element-binding protein.
Aggarwal S; Kim SW; Ryu SH; Chung WC; Koo JS
Cancer Res; 2008 Feb; 68(4):981-8. PubMed ID: 18281471
[TBL] [Abstract][Full Text] [Related]
11. Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis.
Mortazavi F; Lu J; Phan R; Lewis M; Trinidad K; Aljilani A; Pezeshkpour G; Tamanoi F
BMC Cancer; 2015 May; 15():381. PubMed ID: 25956913
[TBL] [Abstract][Full Text] [Related]
12. TAZ negatively regulates the novel tumor suppressor ANKRD52 and promotes PAK1 dephosphorylation in lung adenocarcinomas.
Lee TF; Liu YP; Lin YF; Hsu CF; Lin H; Chang WC; Pan CM; Chou TY; Wu CW
Biochim Biophys Acta Mol Cell Res; 2021 Feb; 1868(2):118891. PubMed ID: 33096142
[TBL] [Abstract][Full Text] [Related]
13. PAK1 as a Potential Therapeutic Target in Male Smokers with EGFR-Mutant Non-Small Cell Lung Cancer.
Chung JH; Kim T; Kang YJ; Yoon SH; Kim YS; Lee SK; Son JH; Son B; Kim DH
Molecules; 2020 Nov; 25(23):. PubMed ID: 33261184
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of N-Acetylglucosaminyltransferase GCNT3 by miR-302b-3p Decreases Non-Small Cell Lung Cancer (NSCLC) Cell Proliferation, Migration and Invasion.
Li Q; Ran P; Zhang X; Guo X; Yuan Y; Dong T; Zhu B; Zheng S; Xiao C
Cell Physiol Biochem; 2018; 50(3):987-1004. PubMed ID: 30355927
[TBL] [Abstract][Full Text] [Related]
15. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
16. ETS-1 Induces Endothelial-Like Differentiation and Promotes Metastasis in Non-Small Cell Lung Cancer.
Zhou X; Zhou R; Zhou H; Li Q; Hong J; Meng R; Zhu F; Zhang S; Dai X; Peng G; Wu G; Li Z
Cell Physiol Biochem; 2018; 45(5):1827-1839. PubMed ID: 29510376
[TBL] [Abstract][Full Text] [Related]
17. PAK1 tyrosine phosphorylation is required to induce epithelial-mesenchymal transition and radioresistance in lung cancer cells.
Kim E; Youn H; Kwon T; Son B; Kang J; Yang HJ; Seong KM; Kim W; Youn B
Cancer Res; 2014 Oct; 74(19):5520-31. PubMed ID: 25125660
[TBL] [Abstract][Full Text] [Related]
18. PAK1 confers chemoresistance and poor outcome in non-small cell lung cancer via β-catenin-mediated stemness.
Chen MJ; Wu DW; Wang YC; Chen CY; Lee H
Sci Rep; 2016 Oct; 6():34933. PubMed ID: 27713506
[TBL] [Abstract][Full Text] [Related]
19. Targeting p21-activated kinase 1 inhibits growth and metastasis via Raf1/MEK1/ERK signaling in esophageal squamous cell carcinoma cells.
Chen L; Bi S; Hou J; Zhao Z; Wang C; Xie S
Cell Commun Signal; 2019 Apr; 17(1):31. PubMed ID: 30971268
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-331-3p inhibits epithelial-mesenchymal transition by targeting ErbB2 and VAV2 through the Rac1/PAK1/β-catenin axis in non-small-cell lung cancer.
Li X; Zhu J; Liu Y; Duan C; Chang R; Zhang C
Cancer Sci; 2019 Jun; 110(6):1883-1896. PubMed ID: 30955235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
